Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 7,982 |
|
|||||
| News | - | ||||||
| Day High | 4.6047 | Low High |
|||||
| Day Low | 4.41 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Lipocine Inc | LPCN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.11 | 2.48% | 4.55 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.42 | 4.41 | 4.6047 | 4.55 | 4.44 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 206 | 7,982 | $ 4.54 | $ 36,217 | - | 2.3101 - 7.15 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:57:06 | 1 | $ 4.71 | USD |
Lipocine Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 24.19M | 5.32M | - | -2.85M | -16.35M | -3.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lipocine News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LPCN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.24 | 5.53 | 4.40 | 4.80 | 39,442 | -0.69 | -13.17% |
| 1 Month | 5.03 | 7.15 | 4.40 | 6.11 | 157,777 | -0.48 | -9.54% |
| 3 Months | 4.03 | 7.15 | 3.20 | 5.71 | 66,374 | 0.52 | 12.90% |
| 6 Months | 2.43 | 7.15 | 2.3101 | 4.94 | 45,235 | 2.12 | 87.24% |
| 1 Year | 5.083 | 7.15 | 2.3101 | 4.83 | 92,029 | -0.533 | -10.49% |
| 3 Years | 24.65 | 32.13 | 2.3101 | 18.34 | 376,097 | -20.10 | -81.54% |
| 5 Years | 31.28 | 59.50 | 2.3101 | 23.43 | 975,615 | -26.73 | -85.45% |
Lipocine Description
| Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company product TLANDO is an oral testosterone replacement therapy TRT. It also has other products in the pipeline such as LPCN 1144 LPCN 1148 and LPCN 1107. |
